| PEIYX | VIVAX | PEIYX / VIVAX | |
| Total Expense Ratio | 0.60 | 0.17 | 353% |
| Annual Report Gross Expense Ratio | 0.60 | 0.17 | 353% |
| Fund Existence | 28 years | 34 years | - |
| Gain YTD | 14.787 | 15.846 | 93% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 56.1B | 262B | 21% |
| Annual Yield % from dividends | 1.06 | 1.70 | 62% |
| Returns for 1 year | 17.09 | 19.18 | 89% |
| Returns for 3 years | 54.23 | 54.85 | 99% |
| Returns for 5 years | 53.87 | 60.79 | 89% |
| Returns for 10 years | 149.78 | 158.94 | 94% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SSPIX | 113.65 | 0.19 | +0.17% |
| SEI S&P 500 Index F (SIMT) | |||
| CGVHX | 30.97 | 0.01 | +0.03% |
| American Funds Global Insight 529-F-3 | |||
| CCSMX | 20.99 | -0.06 | -0.29% |
| Conestoga SMid Cap Investors | |||
| BMSTX | 17.20 | -0.09 | -0.52% |
| MFS Blended Research Mid Cap Eq R3 | |||
| PHPIX | 43.30 | -0.90 | -2.04% |
| ProFunds Pharmaceuticals UltraSector Inv | |||